基石藥業-B(02616.HK)與歐洲百年藥企Gentili就舒格利單抗在西歐和英國達成獨家戰略合作
格隆匯7月8日丨基石藥業-B(02616.HK)發佈公告，基石藥業與一家專注腫瘤領域，並在歐洲市場深耕百年的生物醫藥公司Istituto Gentili(“Gentili”)就舒格利單抗在西歐和英國的商業化達成獨家戰略合作。根據協議條款，Gentili將獲得舒格利單抗在包括十八個EEA國家(奧地利、比利時、塞浦路斯、丹麥、芬蘭、法國、德國、希臘、愛爾蘭、義大利、列支敦士登、盧森堡、馬爾他、荷蘭、挪威、葡萄牙、西班牙及瑞典)，以及英國、安道爾、摩納哥、聖馬利諾及梵蒂岡在內的二十三個國家的獨家商業化權利。
基石藥業將從Gentili獲得首付款、註冊及銷售里程碑付款，交易總金額最高可達1.925億美元。此外，通過向Gentili供應舒格利單抗，公司還將獲得授權區域內舒格利單抗近50%淨銷售額的營收分成。Gentili將負責舒格利單抗在上述地區的註冊及商業化相關活動。
基石藥業首席執行官、研發總裁、執行董事楊建新博士表示：“舒格利單抗是首個在歐盟及英國獲批聯合化療一線治療IV期非小細胞肺癌全人羣(不限組織學分型及PD-L1表達水平)的PD-L1單抗，其針對III期NSCLC的新適應症申請也已獲歐洲藥品管理局(EMA)受理，若順利獲批，舒格利單抗將成爲歐洲第二款治療該適應症的PD-(L)1抗體。
Gentili憑藉深厚的腫瘤學專業積澱、成熟的商業化體系及以患者爲中心的創新理念，成爲加速舒格利單抗在歐洲市場可及性的理想合作夥伴。尤其當前以美國市場定價爲基準的免疫治療藥物，由於受到美國藥品定價體系改革爭議影響，其全球供應與支付模式正面臨新的變數。在此背景下，擴大舒格利單抗這類具有重大臨牀價值療法的可及性，已成爲全球醫療界的當務之急。
迄今我們已在歐洲、中東及非洲、拉丁美洲就舒格利單抗達成四大區域性合作，累計覆蓋六十餘個國家和地區。舒格利單抗的海外上市即將全面啓動，我們將通過深度整合夥伴優勢資源，加速全球佈局和商業化落地，全面釋放舒格利單抗的臨牀價值和市場潛力。與此同時，我們也在積極推動東南亞、加拿大等地區的合作洽談，並持續拓展舒格利單抗其他適應症的註冊申報。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
